News

Video

Imaging and Staging Considerations in Renal Cell Carcinoma

Author(s):

Ulka Vaishampayan, MDAlan Tan, MD

Key opinion leaders discuss the use of brain MRI and bone assessment in the staging and monitoring of patients with renal cell carcinoma.

Related Videos
Sattva S. Neelapu, MD
Sattva S. Neelapu, MD
Rohan Garje, MD
Manmeet Ahluwalia, MD, MBA, FASCO
Petros Grivas, MD, PhD; and Chandler Park, MD, MSc, FACP
Viktor Grünwald, MD, PhD
Daniel M. Halperin, MD, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Timothy Yap, MBBS, PhD, FRCP
David A. Braun, MD, PhD, assistant professor, medicine (medical oncology), Louis Goodman and Alfred Gilman Yale Scholar, member, Center of Molecular and Cellular Oncology, Yale Cancer Center
Video 14 - "Key Takeaways in HER2-Mutated NSCLC"
Related Content
Benjamin L. Maughan, MD, PharmD, of Huntsman Cancer Institute
June 11th 2024

Maughan Spotlights Ways to Reengage the Immune System and Debulking Approaches in RCC

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Benjamin L. Maughan, MD, PharmD
June 7th 2024

Notable RCC Data Presented at ASCO May Shed Light on Key Biomarkers and Combination Approaches

Elias Jabbour, MD, professor, medicine, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
April 8th 2024

FDA Approval Insights: Ponatinib in Ph+ ALL

Benjamin L. Maughan, MD, PharmD
June 6th 2024

Advancements With Combination Therapies in RCC Usher in New Questions

Brian Rini, MD
June 5th 2024

Higher T-Cell Inflamed GEP Values Are Positively Associated with Outcomes For Pembrolizumab/Axitinib in ccRCC